Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.74 |
| ▸ | MEN1 | O00255 | 9/20 | 0.74 |
| ▸ | GAA | P10253 | 7/20 | 0.74 |
| ▸ | GFER | P55789 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.60 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447373 | 1.00 | KMT2A (0.74) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL5445737 | 0.87 | POLB (0.67) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL5445740 | 0.87 | POLB (0.67) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL15936932 | 0.84 | DYRK1A (0.81) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL5449380 | 0.83 | POLB (0.78) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL5449377 | 0.83 | POLB (0.78) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL15702658 | 0.83 | ALDH1A1 (0.72) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL15702610 | 0.80 | KMT2A (0.67) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL5445717 | 0.77 | KMT2A (0.61) | KMT2AMEN1GAAGFERPOLB | |
| SCHEMBL5445714 | 0.77 | KMT2A (0.61) | KMT2AMEN1GAAGFERPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | KMT2A 4413/4885MEN1 2963/4885GAA 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.